AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian NeoplasmsOvarian Cancer
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 211
- Registration Number
- NCT00610714
- Locations
- 🇬🇧
Research Site, Coventry, United Kingdom
Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2100
- Registration Number
- NCT00608218
- Locations
- 🇩🇪
"Nycomed Deutschland GmbH", Würzburg, Germany
Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
Phase 4
Completed
- Conditions
- Postoperative Bariatric Surgery
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00608712
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
Phase 4
Completed
- Conditions
- Non Small Cell Lung Carcinoma
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 156
- Registration Number
- NCT00608868
- Locations
- 🇰🇷
Research Site, Daegu, Korea, Republic of
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
Completed
- Conditions
- Essential HypertensionLeft Ventricular Hypertrophy
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2008-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 686
- Registration Number
- NCT00607633
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2008-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1773
- Registration Number
- NCT00608153
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 197
- Registration Number
- NCT00605267
- Locations
- 🇯🇵
Research Site, Osaka, Japan
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 165
- Registration Number
- NCT00603239
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
Phase 1
Active, not recruiting
- Conditions
- Breast NeoplasmsBreast CancerColon CancerColonic CancerKidney CancerColon NeoplasmsLung CancerMelanoma
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00600496
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 798
- Registration Number
- NCT00600756
- Locations
- 🇹🇷
Research Site, Manisa, Turkey
© Copyright 2025. All Rights Reserved by MedPath